Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study [PDF]
Clinical Ophthalmology, 2018 Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland ...
Doepfner JM +4 more
doaj +5 more sources
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients [PDF]
BMC Ophthalmology, 2020 Background Myopic choroidal neovascularization (CNV) is the most common sight-threatening complication associated with high myopia. The present study evaluated the efficacy and safety of the intravitreal injection of ziv-aflibercept in patients with ...
Amin E. Nawar, Heba M. Shafik
doaj +5 more sources
Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. [PDF]
Eye (Lond), 2022 To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME).A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis between 2016 and 2018 who had a minimum follow-up of 6 months was retrieved and ...
Braimah IZ, Amoaku WM.
europepmc +5 more sources
Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane [PDF]
Case Reports in Ophthalmological Medicine, 2017 Purpose. To study the effect and outcome of intravitreal Ziv-Aflibercept (IVZ) in treatment of Chronic Central Serous Chorioretinopathy (CSCR) related Choroidal Neovascular Membrane (CNVM). Methods.
Nishant Radke +3 more
doaj +5 more sources
Erratum to "Osteonecrosis of the jaw associated with ziv-aflibercept". [PDF]
J Gastrointest Oncol, 2017 Editorial Team
europepmc +5 more sources
Efficacy and safety of Ziv-aflibercept in patients with central retinal vein occlusion
Delta Journal of Ophthalmology, 2021 Background Retinal vein occlusion is one of the most common vascular disorders that can cause visual loss. It is classified into central retinal vein occlusion (CRVO) and branch retinal vein occlusion.
Amin E Nawar, Heba M Shafik
doaj +2 more sources
Ziv-aflibercept in metastatic colorectal cancer. [PDF]
Biologics, 2014 The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with
Patel A, Sun W.
europepmc +7 more sources
Ziv-aflibercept in macular disease [PDF]
British Journal of Ophthalmology, 2015 Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept.
Ahmad M Mansour
exaly +5 more sources
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors [PDF]
Journal for ImmunoTherapy of Cancer, 2022 Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis.
Howard Streicher +13 more
doaj +2 more sources
Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection [PDF]
BMC Ophthalmology, 2022 Background Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept.
Amin E. Nawar +2 more
doaj +2 more sources